Literature DB >> 32055851

Dual blockade of STAT3 and EGFR: a key to unlock drug resistance in glioblastoma?

Sabrina Fritah1, Simone P Niclou1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32055851      PMCID： PMC7158645          DOI： 10.1093/neuonc/noaa039

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  13 in total

1.  Stattic: a small-molecule inhibitor of STAT3 activation and dimerization.

Authors:  Jochen Schust; Bianca Sperl; Angela Hollis; Thomas U Mayer; Thorsten Berg
Journal:  Chem Biol       Date:  2006-11

Review 2.  The ABC of BTC: structural properties and biological roles of betacellulin.

Authors:  Maik Dahlhoff; Eckhard Wolf; Marlon R Schneider
Journal:  Semin Cell Dev Biol       Date:  2014-01-15       Impact factor: 7.727

Review 3.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

4.  Betacellulin (BTC) Biases the EGFR To Dimerize with ErbB3.

Authors:  Jamie S Rush; Joanne L Peterson; Brian P Ceresa
Journal:  Mol Pharmacol       Date:  2018-09-24       Impact factor: 4.436

5.  EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

Authors:  Qi-Wen Fan; Christine K Cheng; W Clay Gustafson; Elizabeth Charron; Petra Zipper; Robyn A Wong; Justin Chen; Jasmine Lau; Christiane Knobbe-Thomsen; Michael Weller; Natalia Jura; Guido Reifenberger; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

Review 6.  STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics.

Authors:  Ahmad A Zulkifli; Fiona H Tan; Tracy L Putoczki; Stanley S Stylli; Rodney B Luwor
Journal:  Mol Cell Endocrinol       Date:  2017-01-12       Impact factor: 4.102

7.  Betacellulin promotes cell proliferation in the neural stem cell niche and stimulates neurogenesis.

Authors:  María Victoria Gómez-Gaviro; Charlotte E Scott; Abdul K Sesay; Ander Matheu; Sarah Booth; Christophe Galichet; Robin Lovell-Badge
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-09       Impact factor: 11.205

Review 8.  Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma.

Authors:  Igor Makhlin; Ryan D Salinas; Daniel Zhang; Fadi Jacob; Gou-Li Ming; Hongjun Song; Deeksha Saxena; Jay F Dorsey; MacLean P Nasrallah; Jennifer Jd Morrissette; Zev A Binder; Donald M O'Rourke; Arati S Desai; Steven Brem; Stephen J Bagley
Journal:  CNS Oncol       Date:  2019-11-15

9.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

10.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Authors:  Darren A E Cross; Susan E Ashton; Serban Ghiorghiu; Cath Eberlein; Caroline A Nebhan; Paula J Spitzler; Jonathon P Orme; M Raymond V Finlay; Richard A Ward; Martine J Mellor; Gareth Hughes; Amar Rahi; Vivien N Jacobs; Monica Red Brewer; Eiki Ichihara; Jing Sun; Hailing Jin; Peter Ballard; Katherine Al-Kadhimi; Rachel Rowlinson; Teresa Klinowska; Graham H P Richmond; Mireille Cantarini; Dong-Wan Kim; Malcolm R Ranson; William Pao
Journal:  Cancer Discov       Date:  2014-06-03       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.